Provided by Tiger Trade Technology Pte. Ltd.

Natera

345.34
-5.4400-1.55%
Post-market: 345.340.00000.00%19:53 EDT
Volume:1.43M
Turnover:498.01M
Market Cap:49.46B
PE:-251.54
High:357.15
Open:350.18
Low:343.28
Close:350.78
52wk High:357.15
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.33
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:27.15
PE(LYR):-226.18

Loading ...

Natera, Aveta Biomics announce strategic partnership

TIPRANKS
·
Jun 29

Natera Partners with Aveta Biomics on Phase 3 Apg-157 Head and Neck Cancer Trial

Reuters
·
Jun 29

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of Apg-157 in Head and Neck Cancer

THOMSON REUTERS
·
Jun 29

Natera - Phase 3 Trial Expected to Begin Enrollment in Second Half of 2026

THOMSON REUTERS
·
Jun 29

Natera Director Herm Rosenman Disposes of 16,530 Shares for $4.13 Million

Reuters
·
Jun 27

Natera Price Target Announced at $310.00/share by Bernstein

Dow Jones
·
Jun 26

Natera Inc : Bernstein Resumes Coverage with Outperform Rating; Price Target $310

THOMSON REUTERS
·
Jun 26

Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial

Reuters
·
Jun 25

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

THOMSON REUTERS
·
Jun 25

Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026

THOMSON REUTERS
·
Jun 25

Movement Alert|Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan

Market Focus
·
Jun 25

Street View: Japan Nod for Natera's Cancer Test Meaningful, but Payoff Seen Later

Reuters
·
Jun 24

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

MT Newswires Live
·
Jun 24

Natera : Barclays Cuts Target Price to $260 from $280

THOMSON REUTERS
·
Jun 24

Natera announces Signatera receives regulatory approval in Japan

TIPRANKS
·
Jun 24

BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer

Reuters
·
Jun 24

Natera Signatera colorectal cancer MRD test wins Japan PMDA approval

Reuters
·
Jun 24

Natera Inc - Natera Expects to Commercially Launch Signatera for Crc in Japan by End of 2026

THOMSON REUTERS
·
Jun 24

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

THOMSON REUTERS
·
Jun 24

Natera price target raised to $270 from $250 at BTIG

TIPRANKS
·
Jun 24